What part don't you get?
This is specifically and ONLY for Medicaid recipients.
They already pay $0-$10 copay for these prescription drugs.
Does not apply to
Medicare. Far bigger pool. Or private employer based health insurance, an even bigger pool.
Additionally, most low income seniors can get most prescription drugs for close to 0$ anyway.
Example:
Mom was put on Eliquis while on Medicare
It was $600 p/mo …. For 1 month. Until I called BMSqib and told them her annual income was about $18,000.
From that point on for the last 3 years of her life they sent a free 6 month supply every Jan and July
Are there exceptions? I’m sure there are.
But this doesn’t effect many people
==
President Trump on Friday announced new agreements with nine pharmaceutical manufacturers aimed at reducing certain prescription drug prices.
"Starting next year, American drug prices will come down fast and furious and will soon be the lowest in the developed world," Mr. Trump said Friday at the White House.
Under the deal, the nine manufacturers will offer their drugs to
Medicaid recipients at most-favored-nation discounts, a policy that requires the prices to match those paid by patients in other developed nations. The nine companies will also offer medicines "at a deep discount off the list price" to Americans through TrumpRx, according to the White House.
The Trump administration plans to offer tariff exemptions to the drugmakers for three years in exchange for the MFN pricing commitments.
According to a White House fact sheet, the drugs that will be covered include treatments for chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease, hepatitis B and C, human immunodeficiency virus and certain cancers.
Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Science, GSK, Merck, Novartis, and Sanofi will sell drugs on TrumpRx, the administration's discount drug pricing program. TrumpRx — which the administration has said will launch early next year — will not sell drugs directly, but instead will direct consumers to lower prices elsewhere.
Senior administration officials said that roughly 30-40% of Medicaid drug prices are currently higher than what patients in other wealthy nations pay, mostly Europeans, and that the prices of those drugs will drop.
The president has previously announced agreements with
AstraZeneca, EMD Serono,
Eli Lilly, Novo Nordisk and Pfizer. The White House said it has made MFN deals with 14 of the 17 biggest drug manufacturers in the world. The three drugmakers that were not part of the announcement are AbbVie, Johnson & Johnson and Regeneron, but the president said that deals involving the remaining three could be announced at another time.
"[The policy] affects every American so that they have the dignity to access the same medical innovations that our tax dollars helped develop," a White House official said. "This is about healthcare fairness."
But questions remain about how the president's deals with drugmakers will work — and who will feel the difference at the pharmacy counter.
Most-favored-nation pricing could have a muted impact on Medicaid patients, experts say, because the program already has a statutory "best price" protection that guarantees the lowest price offered to any U.S. commercial payer. Also, while it could save states money, Medicaid users typically don't pay out-of-pocket for their medication.
Medicaid recipients are "starting out at prices well below the averages seen in the U.S. market," Darius Lakdawalla, chief scientific officer at the University of Southern California's Schaeffer Center,
pointed out to CBS News after the president announced the Pfizer deal.
The White House said the new agreement represents more than $150 billion in new investment commitments in manufacturing and research and development in the U.S.
======================================
TrumpRx is a federal government initiative centered around a new website, TrumpRx.gov, slated to launch in early 2026. The primary stated goal is to lower the cost of prescription drugs for Americans by creating a new pathway for purchasing medications directly from manufacturers at discounted...
govfacts.org
The government-operated website will not directly sell or distribute medications. Instead,
it’s designed to function as a search portal. Consumers can use the site to look up their prescriptions and, if a drug is part of the program,
they will be redirected to the pharmaceutical manufacturer’s own direct-to-consumer platform to complete the purchase. This portal model keeps the government out of the complex logistics of the pharmaceutical supply chain.
(*See my example on Mom and Eliquis)
-Who benefits: Uninsured and high-deductible consumers may save;
most insured patients see little change.
-The Payment models: Bypassing Insurance: A defining feature of the TrumpRx model is that
all purchases are cash-pay, out-of-pocket transactions. The system is explicitly designed to “bypass traditional intermediaries” such as health insurers and Pharmacy Benefit Managers (PBMs), the third-party administrators that manage prescription drug benefits for health plans.
-The Question of Deductibles: For the majority of Americans who have health insurance, a crucial financial consideration is that
payments made for drugs purchased through TrumpRx would almost certainly not count toward their health insurance deductibles or annual out-of-pocket maximums.
Health insurance plans typically only credit payments toward these limits when they are for covered services and drugs processed through their approved network of pharmacies and providers.
www.foxnews.com
